Introduction {#sec1}
============

Primary immunodeficiency diseases (PIDs) are a heterogeneous group of immune disorders that affect distinct components of the humeral and cellular arms of the immune system. PIDs are caused by hereditary or genetic defects, and, although some disorders present at birth or in early childhood, the disorders can affect everybody, regardless of age or gender \[[@cit0001]-[@cit0003]\].

It is known that PID patients suffer from a variety of clinical complications including infectious and non-infectious diseases \[[@cit0004], [@cit0005]\]. PID patients are mainly characterized by increased susceptibility to infections because there are defects in neutrophils, macrophages, complement proteins and lymphocyte subsets \[[@cit0001], [@cit0006], [@cit0007]\]. Infections involving multiple organs, such as the respiratory tract, gastrointestinal tract (chronic diarrhea and enteropathy), central nervous system (meningitis and encephalitis), skin (cellulitis, impetigo and recurrent abscesses), and septicemia, are more prevalent in PID patients \[[@cit0008]\]. Among the infectious complications, respiratory signs and symptoms present a significant cause of mortality and morbidity among patients suffering from PIDs and they are observed in both children and adults. These complications can affect primarily either the upper respiratory tract (e.g., sinusitis and otitis media) or lower respiratory tract (e.g., pneumonia, bronchiectasis, and interstitial lung diseases). The lower respiratory tract complications are usually considered to be more important and also more specific for PID patients' prognosis \[[@cit0009], [@cit0010]\].

PID patients may also present with a variety of non-infectious complications including malignant, allergic, inflammatory, and autoimmune manifestations \[[@cit0011], [@cit0012]\]. In some cases, these non-infectious manifestations (such as autoimmune diseases) may be the first or the predominant clinical manifestation of the underlying immunodeficiency \[[@cit0013]\]. Therefore, early diagnosis and adequate therapy are the key facts for survival and a better quality of life in PID patients, while the delay in diagnosis and inadequate management of these disorders may lead to permanent organ damage \[[@cit0014], [@cit0015]\].

This study aimed to evaluate the clinical findings of infectious and non-infectious complications in eight main types of PIDs: common variable immunodeficiency (CVID), X-linked agammaglobulinemia (XLA), hyper-IgM syndrome (HIgM), hyper-IgE syndrome (HIES), chronic granulomatous disease (CGD), ataxia telangiectasia (AT), hereditary angioedema (HAE) and leukocyte adhesion deficiency (LAD).

Material and methods {#sec2}
====================

Patients {#sec2.1}
--------

This retrospective cohort study was performed on patients with PIDs who were diagnosed and treated in the Research Center for Immunodeficiencies at the Children's Medical Center affiliated to Tehran University of Medical Sciences. The study was reviewed and approved by the Ethics Committee of the Tehran University of Medical Sciences. PID patients were diagnosed based on the Pan-American Group for Immunodeficiency (PAGID) and the European Society for Immunodeficiency (ESID) diagnostic criteria \[[@cit0016]\]. Patients then were registered in the national database \[[@cit0008]\] and then classified into different categories of PIDs. A selected group of patients with high incidence (*n* \> 10 patients) were enrolled in this study. Therefore, available patients with diagnosis of CVID, XLA, HIgM, HIES, CGD, AT, HAE and LAD were selected. Severe combined immunodeficiency patients were not included because of the bias of heterogeneity of clinical condition and follow-up times depend on the availability of hematopoietic stem cell transplantation. We designed a comprehensive questionnaire that included demographic information including name, age at clinical presentation, age at diagnosis at our clinic and age at last follow-up, diagnosis, family history of PID, infections, associated autoimmune disease and allergy, enteropathy, lymphoproliferative and malignancies. The questionnaire was completed for all patients. Moreover, laboratory test data including the initial immunological work-up at the time of referral to our research center were also recorded for each patient.

Statistical analyses {#sec2.2}
--------------------

Statistical analyses were performed using the SPSS software package, version 22 (SPSS Inc., Chicago, IL, USA). To report the results, values were expressed as frequency (number and percentage), mean ±SD and median (IQR), as appropriate. Fisher's exact test and the chi-square test were used for comparison of categorical variables, whereas the t-test and one-way ANOVA were used to compare numerical variables. Pearson's and Spearman correlation coefficient were calculated for assessment of correlations between quantitative and qualitative variables, respectively. A *p-*value \< 0.05 was considered significant.

Results {#sec3}
=======

Demographic and characteristic baseline {#sec3.1}
---------------------------------------

In this retrospective study, 202 PID patients (128 males and 74 females) with antibody deficiency (XLA, CVID, HIgM; *n* = 91), congenital defects of phagocyte (CGD and LAD; *n* = 32), complement deficiency (HAE; *n* = 8), and combined immunodeficiencies (AT and HIES; *n* = 71) were evaluated. Demographic and corresponding immunologic data for these eight types of PIDs are presented in [Table 1](#t0001){ref-type="table"}. The median age of these PID patients was 14 (3.0-40.0) years. The median diagnostic delay was found to be 31.0 (6.0-264.0) months, while the longest and shortest delay in diagnosis was observed in patients with HAE and LAD, respectively. There was a remarkable difference in the duration of diagnostic delay between patients with CVID (46.5 months) compared to XLA (24.0 months, *p* = 0.043), HIgM (18.0 months, *p* = 0.078), CGD (7.5 months, *p* = 0.035) and LAD (3.5 months, *p* = 0.002). A significant correlation was observed between diagnostic delay and bronchiectasis in CVID patients (*r* = 0.323, *p* = 0.042). However, no significant correlation was found between delay in diagnosis and chronic diarrhea in patients with CVID, although this association was borderline significant in XLA patients (*r* = 0.354, *p* = 0.055). Parental consanguinity was observed in 50.4% of cases. Among them, LAD patients had the highest rate (100% of cases) while XLA patients had the lowest (36.7% of cases).

###### 

Demographic and corresponding immunologic data for PID patients

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Factor                     Total (*N* = 202)   XLA (*n* = 30)   CVID (*n* = 40)   HIgM (*n* = 21)   CGD (*n* = 20)   LAD (*n* = 12)   AT (*n* = 20)   HIES (*n* = 51)   HAE (*n* = 8)
  -------------------------- ------------------- ---------------- ----------------- ----------------- ---------------- ---------------- --------------- ----------------- ---------------
  Sex ratio (M/F)            128/74              30/0             25/15             17/4              13/7             6/6              10/10           25/26             2/6

  Age (years)                14.0\               16.0\            16.0\             9.0\              9.0\             9.5\             10.0\           14.0\             23.5\
                             (3.0-40.0)          (7.7-25.5)       (12.0-24.5)       (3.0-12.0)        (6.5-18.7)       (3.7-13.0)       (8.25-18.5)     (3.0-22.0)        (3.1-40.5)

  Delay diagnosis (months)   31.0\               24.0\            46.5\             18.0\             7.5\             3.5\             44.0\           84.0\             60.4\
                             (6.0-264.0)         (5.5-40.5)       (19.0-81.5)       (2.5-48.0)        (2.2-19.5)       (1.2-14.5)       (13.5-60.0)     (6.1-191.0)       (1.3-264.0)

  Consanguinity,n (%)        102 (50.4)          11 (36.7)        25 (62.5)         13 (61.9)         13 (65.0)        12 (100.0)       17 (85.0)       10 (19.6)         1 (12.5)

  IgG (mg/dl)                250\                100\             242\`\            70\               1572\            781\             700\            1396\             1420\
                             (42-607)            (18-290)         (64-334)          (14-129)          (960-1935)       (616-1800)       (550-1093)      (740-2010)        (941-2010)

  IgA (mg/dl)                9\                  5\               7\                8\                182\             131\             36\             200\              140\
                             (3-38)              (0-20)           (2-22)            (5-20)            (95-414)         (89-378)         (5-116)         (150-340)         (105-225)

  IgM (mg/dl)                49\                 5\               17\               271\              153\             146\             224\            140\              230\
                             (10-186)            (0-17)           (6-35)            (115-1308)        (128-218)        (87-194)         (126-313)       (58-230)          (68-345)

  IgE (IU/ml)                2.5\                4\               1\                1\                105\             \-               4\              9040\             54\
                             (1-11)              (1-6)            (0-3)             (0-3)             (15-792)                          (1-10)          (1700-15720)      (10-118)
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Ig -- immunoglobulins; XLA -- X-linked agammaglobulinemia; CVID -- common variable immune deficiency; HIgM -- hyper-IgM syndrome; HIES -- hyper-IgE syndrome; HAE -- hereditary angioedema; CGD -- chronic granulomatous disease; AT -- ataxia-telangiectasia; LAD -- leukocyte adhesion deficiency Note. For age, delay diagnosis and Ig levels the median is shown with 25^th^ and 75^th^ percentiles

Infectious complications {#sec3.2}
------------------------

Infectious complications were more frequent than non-infectious complications in PID patients. Pneumonia (69.3%) and otitis media (56.9%) were the main infectious problems in PID patients, especially in patients with antibody deficiencies. A detailed report of infectious complications in eight different groups is summarized in [Table 2](#t0002){ref-type="table"}. The most frequent infectious complications in XLA and HIgM patients were pneumonia (66.7% and 76.2%, respectively) and otitis media (63.3% and 57.1%, respectively). However, pneumonia (82.5%) and otitis media (67.5%) were more common in CVID than other disorders. There were diverse infectious manifestations in CVID patients; in addition to pneumonia and otitis media, chronic cough (65.0%), bronchiectasis (50.0%), and chronic diarrhea (47.5%) were also frequently documented in these patients. In CGD patients, abscess (100.0%), pneumonia (75.0%), skin ulcers (55.5%), and osteomyelitis (30.0%) were seen more, while in LAD patients, skin ulcers (83.3%), omphalitis (66.7%), abscess (41.7%) and mouth sores (41.7%) were the most common findings. Similar to antibodydeficient patients, pneumonia (65.0%) and otitis media (50.0%) were the most common infectious manifestations in AT patients. Bronchiectasis was seen in 33% of PAD patients and was significantly more common than other PIDs (*p* \< 0.001). There was significantly higher prevalence of bronchiectasis in CVID in comparison with XLA (*p* = 0.004) and HIgM (*p* = 0.048). Likewise, a higher rate of chronic diarrhea was observed in CVID patients than XLA (*p* = 0.076), HIgM (*p* = 0.072) and AT (*p* = 0.039). Interestingly, septicemia was not reported in any of these PID patients.

###### 

Infectious complications among PID patients

  Infectiouscomplications   Total (*N* = 202)   XLA (*n* = 30)   CVID (*n* = 40)   HIgM (*n* = 21)   CGD (*n* = 20)   LAD (*n* = 12)   AT (*n* = 20)   HIES(*n* = 51)   HAE (*n* = 8)
  ------------------------- ------------------- ---------------- ----------------- ----------------- ---------------- ---------------- --------------- ---------------- ---------------
  Otitis media              115 (56.9)          19 (63.3)        27 (67.5)         12 (57.1)         4 (20.0)         2 (16.7)         10 (50.0)       40 (78.5)        1 (12.5)
  Pneumonia                 140 (69.3)          20 (66.7)        33 (82.5)         16 (76.2)         15 (75.0)        3(25.0)          13 (65.0)       40 (78.5)        0 (0.0)
  Chronic cough             86 (42.5)           17 (56.7)        26 (65.0)         8 (38.1)          1 (5.0)          0 (0.0)          3 (15.0)        30 (58.8)        1 (12.5)
  Abscess                   78 (38.6)           4(13.3)          5 (12.5)          3 (14.3)          20 (100.0)       5 (41.7)         2 (10.0)        39 (76.4)        0 (0.0)
  Osteomyelitis             7 (3.4)             1 (3.3)          0 (0.0)           0 (0.0)           6 (30.0)         0 (0.0)          0 (0.0)         0 (0.0)          0 (0.0)
  Meningitis                10 (4.9)            6 (20.0)         4 (10.0)          0 (0.0)           0 (0.0)          0 (0.0)          0 (0.0)         0 (0.0)          0 (0.0)
  Septic arthritis          23 (11.3)           6 (20.1)         7 (17.5)          4 (19.0)          4 (20.0)         2 (16.5)         0 (0.0)         0 (0.0)          0 (0.0)
  Chronic diarrhea          47 (23.2)           8 (26.7)         19 (47.5)         5 (23.8)          7 (35.0)         4 (33.3)         4 (20.0)        0 (0.0)          0 (0.0)
  Skin ulcers               64 (31.6)           0 (0.0)          1 (2.5)           0 (0.0)           11 (55.5)        10 (83.3)        0 (0.0)         41 (80.3)        1 (12.5)
  Omphalitis                8 (3.9)             0 (0.0)          0 (0.0)           0 (0.0)           0 (0.0)          8 (66.7)         0 (0.0)         0 (0.0)          0 (0.0)
  Mouth sores               37 (18.3)           0 (0.0)          2(5.0)            2(9.5)            2 (10.0)         5 (41.7)         3 (15)          23 (45.1)        0 (0.0)
  Bronchiectasis            39 (37.9)           5 (16.7)         20 (50.0)         5 (23.8)          1 (5.0)          0 (0.0)          0 (0.0)         8 (15.7)         0 (0.0)

XLA -- X-linked agammaglobulinemia; CVID -- common variable immune deficiency; HIES -- hyper-IgE syndrome; HAE -- hereditary angioedema; HIgM -- hyper- IgM syndrome; CGD -- chronic granulomatous disease; AT -- ataxia-telangiectasia; LAD -- leukocyte adhesion deficiency

Non-infectious complications {#sec3.3}
----------------------------

In this study, 22 PID patients (10.9%) had only non-infectious manifestations (2 CVID, 1 XLA, 1 HIgM, 1 AT, 10 HIES and 7 HAE patients). Among the non-infectious complications in PID patients, eczema (28.7%), clubbing (15.8%), splenomegaly (14.3%), and hepatomegaly (9.9%) were the most common. Non-infectious complications in the study groups are summarized in [Table 3](#t0003){ref-type="table"}. Splenomegaly (40%) and hepatomegaly (30%) were more common in CGD patients than others. The most common complications in XLA patients were JRA (13.3%), eczema (6.7%), and hepatomegaly (6.7%), while in HIgM patients splenomegaly (14.3%), hepatomegaly (14.3%), and neutropenia (23.8%) were more prevalent. Splenomegaly (35.0%), hepatomegaly (15.0%) and autoimmunity including AIHA (15.0%), ITP (12.5%) and JRA (17.5%) were the most common findings in CVID patients. Malignancy was only reported in two (5%) patients with CVID and one (1.9%) with HIES. As described above, CVID was most commonly associated with autoimmunity. There was a significantly higher prevalence of autoimmunity manifestations in CVID compared to XLA (*p* = 0.004), HIgM (*p* = 0.009), CGD (*p* = 0.011), AT (*p* = 0.011) and LAD (*p* = 0.023).

###### 

Non-infectious complications among PID patients

  Non-infectiouscomplications   Total (*N* = 202)   XLA (*n* = 30)   CVID (*n* = 40)   HIgM (*n* = 21)   CGD (*n* = 20)   AT (*n* = 20)   LAD (*n* = 12)   HIES (*n* = 51)   HAE (*n* = 8)
  ----------------------------- ------------------- ---------------- ----------------- ----------------- ---------------- --------------- ---------------- ----------------- ---------------
  Splenomegaly                  29 (14.3)           1 (3.3)          14 (35.0)         3 (14.3)          8 (40.0)         1 (5.0)         2 (16.7)         0 (0.0)           0 (0.0)
  Hepatomegaly                  20 (9.9)            2 (6.7)          6 (15.0)          3 (14.3)          6 (30.0)         1 (5.0)         2 (16.7)         0 (0.0)           0 (0.0)
  JRA                           12 (5.9)            4 (13.3)         7 (17.5)          1 (4.8)           0 (0.0)          0 (0.0)         0 (0.0)          0 (0.0)           0 (0.0)
  AIHA                          7 (3.4)             1 (3.3)          6 (15.0)          0 (0.0)           0 (0.0)          0 (0.0)         0 (0.0)          0 (0.0)           0 (0.0)
  ITP                           8 (3.9)             1 (3.3)          5 (12.5)          0 (0.0)           1 (5.0)          1 (5.0)         0 (0.0)          0 (0.0)           0 (0.0)
  Neutropenia                   9 (4.4)             3 (10.0)         0 (0.0)           5(23.8)           0 (0.0)          0 (0.0)         0 (0.0)          1 (19)            1 (12.5)
  Hypothyroidism                2 (0.9)             0 (0.0)          2(5.0)            0 (0.0)           0 (0.0)          0 (0.0)         0 (0.0)          0 (0.0)           0 (0.0)
  Diabetes                      1 (0.4)             0 (0.0)          0 (0.0)           1 (4.8)           0 (0.0)          0 (0.0)         0 (0.0)          0 (0.0)           0 (0.0)
  Vitiligo                      1 (0.4)             0 (0.0)          1 (2.5)           0 (0.0)           0 (0.0)          0 (0.0)         0 (0.0)          0 (0.0)           0 (0.0)
  Alopecia                      3 (1.4)             1 (3.3)          2(5.0)            0 (0.0)           0 (0.0)          0 (0.0)         0 (0.0)          0 (0.0)           0 (0.0)
  Eczema                        58 (28.7)           2 (6.7)          1 (2.5)           0 (0.0)           0 (0.0)          2 (10.0)        0 (0.0)          48 (94.1)         5 (62.5)
  Clubbing                      32 (15.8)           4 (13.3)         16 (40)           5(23.8)           3 (15)           1 (5)           0 (0.0)          3 (5.8)           0 (0.0)
  Paralysis                     2 (0.9)             2 (6.6)          0 (0.0)           0 (0.0)           0 (0.0)          0 (0.0)         0 (0.0)          0 (0.0)           0 (0.0)
  Malignancy                    3 (1.4)             0 (0.0)          2(5.0)            0 (0.0)           0 (0.0)          0 (0.0)         0 (0.0)          1 (19)            0 (0.0)

Discussion {#sec4}
==========

PIDs are a heterogeneous group of genetic immune disorders. The number of these disorders is increasing annually and over 270 PIDs are defined so far \[[@cit0017]\]. PIDs are principally manifested by vulnerability to recurrent infection \[[@cit0013]\]. However, there are multiple noninfectious features accompanied by these conditions \[[@cit0011], [@cit0018]\].

This is a report of infectious and noninfectious manifestations in a group of PIDs including patients with antibody deficiency (XLA, HIgM and CVID), phagocytic disorders (CGD and LAD) and combined immunodeficiency (AT and HIES) and HAE. To the best of our knowledge, this is the first survey on the infectious and non-infectious complications of different types of PID.

Most of the PIDs present with regular infections in upper and lower respiratory tracts that physicians usually do not take any notice of except for having a strong suspicion and doing an early diagnostic workup; otherwise these conditions will be diagnosed with a significant delay \[[@cit0013]\]. Diagnostic delay (mean: 24 months) was an important finding in this survey. Patients with CVID and AT had the longest mean duration (46.5 months and 44 months) of delay in diagnosis whereas LAD was diagnosed at the earliest time (3.5 months). This discrepancy could be explained by the severity and features of the diseases. The first manifestation of LAD is delayed separation of the umbilical cord and cutaneous ulcers \[[@cit0018]\]. Therefore, it is predictable that LAD would be diagnosed much earlier than CVID, XLA and AT with the vague presentations in the early months of life. Consanguinity of the parents was frequently found in the patients. All of our LAD patients had related parents, but this variable was found to be positive in about a third of patients with XLA. This could be explained by the pattern of inheritance that is autosomal recessive in the LAD and X-linked in XLA.

The respiratory system is substantially the most prominent target organ for both infectious and noninfectious complications of PIDs, and primary antibody deficiencies are the leading cause of these complications \[[@cit0009]\]. Regarding the infectious complications, pneumonia was generally the most common problem in our patients, and CVID was mainly associated with pneumonia while LAD was least often accompanied by pneumonia. HIgM, CGD, XLA and AT were also associated with pneumonia, in descending order. The lung is not the first target in LAD, and involvement of superficial tissues including skin and mucus membranes is more predominant in this entity. This could also be explained by the younger age of the LAD patients at the time of diagnosis compared to the CVID patients with the longest delay of diagnosis. Sinusitis and otitis media were found to be the most common infections in CVID patients with long-term diagnostic delay, while chronic diarrhea (36%) was the most common infection in CVID patients with shorter duration of diagnostic delay in the previous study by Aghamohammadi *et al.* They also found that pneumonia was significantly more frequent in the CVID patients with a long duration of delay in diagnosis \[[@cit0019]\]. Oksenhendler *et al*. evaluated the infections in 252 CVID patients; 91% of their patients had respiratory problems, bronchitis (69%), sinusitis (63%) and pneumonia (58%) being the most common infections \[[@cit0020]\].

Bronchiectasis, which generally is a complication of recurrent uninhibited pulmonary infections, is considered as a clue for the diagnosis of PIDs \[[@cit0009]\]. A significant increase in bronchiectasis occurrence has been reported in a group of 47 CVID patients with delayed diagnosis \[[@cit0019]\]. We found bronchiectasis in half of the patients with CVID, and its occurrence in patients with HIgM and XLA was lower, while none of the patients with AT and LAD had bronchiectasis. This might be explained by the more frequent pneumonia in CVID, HIgM and XLA. In addition, the older age of the CVID and XLA patients in our survey compared to HIgM and CGD could be an explanation for the difference between these conditions. Our findings are comparable with previous studies on the infectious complications in CVID \[[@cit0019]-[@cit0021]\]. The younger age at the diagnosis of LAD patients and the lower propensity for lung involvement in this disease could be the reason for the lack of bronchiectasis in this group. Aghamohammadi *et al*. found bronchiectasis as the principle complication in their study group, and it was more significantly increased in the CVID patients with long duration of delay diagnosis (58% in long lasting diagnostic delay compared to 34% in the short diagnostic delay) \[[@cit0019]\]. Habahbeh *et al*. found pneumonia (62.3%), otitis media (49.1%) and sinusitis (34%) as the most common infections in 53 patients with primary antibody deficiency \[[@cit0021]\].

Pulmonary infections are usually observed in AT patients \[[@cit0018]\]. Although bronchiectasis is expected to be a manifestation of this disease, we did not find this complication in our patients. It needs to be studied in future to find other probable risk factors such as genetic characteristics for bronchiectasis other than recurrent infection in PID.

Recurrent otitis media (4 or more episode of ear infection in a year) is considered one of the warning signs of PIDs \[[@cit0009]\]. Otitis media was observed in more than half (56.9%) of our study group. CVID (67.5%), XLA (63.3%), HIgM (57.1%) and AT (50%) were more associated with otitis media, while otitis media frequency in LAD (16.7%) and CGD (20%) was lower. This observation is due to the importance of humoral immunity in the defense against the encapsulated bacteria that are the leading cause of otitis media.

Skin and mucosal manifestations including ulcer and abscess formation are frequently considered the common features of phagocytic disorders \[[@cit0013]\]. Skin ulcer and abscess were found in all of the CGD patients in this study. However, LAD patients presented with omphalitis (66.7%), mouth sores (41.7%) and skin ulcer (83.3%).

According to the non-infectious complications, splenomegaly, clubbing and hepatomegaly were more common than others. CVID was the most predisposing immunodeficiency for these signs. Chronic infection and immune dysregulation could explain the higher frequency of the hepatosplenomegaly in CVID \[[@cit0022]\]. Clubbing is frequently considered a common feature of chronic lung infections and bronchiectasis \[[@cit0023]\]. Therefore, the higher prevalence of a chronic cough, pneumonia and bronchiectasis in our patients with CVID could be the reason for more frequent clubbing in these patients compared to other groups.

CVID is identified as an immune dysregulation entity that is commonly associated with different features of autoimmunity involving hematologic, cutaneous, endocrinologic, gastrointestinal and rheumatologic systems \[[@cit0022], [@cit0024]-[@cit0026]\]. We found autoimmune disorders (JRA, ITP, and AIHA) in patients with CVID more frequent than other study groups. Cytopenias were commonly seen in the CVID group including AIHA (15%) and ITP (12.5%) in addition to neutropenia in XLA (10%) and HIgM (23.8%) in the present study. Autoimmune cytopenias (22%) were the most common autoimmunity in primary antibody deficiencies in the Habahbeh *et al*. survey. They found these cytopenias in 50% of the CVID group \[[@cit0021]\]. Oksenhendler *et al*. also found autoimmune cytopenias in 18% of CVID patients \[[@cit0020]\]. Wang and coworkers found a frequency of autoimmune cytopenias (AIHA and ITP) of 11% in 326 CVID patients \[[@cit0027]\]. These are similar to our finding that CVID was more commonly associated with AIHA and ITP.

Other non-infectious manifestations of immunodeficiency including skin disorders (alopecia, vitiligo and eczema), endocrine disorders (hypothyroidism and diabetes), paralysis and malignancy were found to be uncommon, and CVID was the only predisposing PID for most of them.

Conclusions {#sec5}
===========

The results of our study showed that PID patients are at risk of multiple infectious and non-infectious problems. Timely diagnosis of PIDs not only improves their outcome and quality of life, but also helps to prevent these troubling complications. Recurrent, severe infections and autoimmune disorders could be the first manifestation of PIDs. Considering PID in the differential diagnosis of these problems leads to minimizing the delay in diagnosis and improvement the prognosis in PIDs. More detailed studies with more patients and a broader list of studied PIDs are required to find the best way and time of diagnosis and appropriate preventive measures.
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